Platech

Platelet Technologies


WE ARE
PLATECH

WE ARE PLATECH

WE MAKE hPROTEINS!

…for life sciences and biomedicine industry.

First, we harvest human growth factors **from human cells**.

We are now targeting many other human proteins t**hat cannot or are complex to produce**…

Challenges in Human Protein Bioproduction

- Current platforms make proteins for **R&D and clinical trials that look human, but are not.**
- In the niche of **difficult-to-express proteins** (DhPs), we need a better solution: authentically human proteins.



Platech

Difficult-to-Express Human Proteins

01

Sources & Platforms

Nonhuman resources cause inconsistency, forcing **2–3 extra experiments or costly products, leading to 60–100% excess.**

02

Scalability & Consistency

03

Biologics Precision

04

Costs

30% Laboratory Budget, representing over **$65 billion globally** in lost control of cell culture.

Introducing a

New Megakaryoblastic Platform

TO PRODUCE

Difficult-to-Express Human Proteins!

Platech

New Megakaryoblastic Platform

to produce

Difficult-to-Express Human Proteins!

Platech

TRL 7
Production tested at semi-industrial level

A new Human-Based Biotech Cell Platform

✓ Ready for industrialization

✓ Aligned for partnership.

✓ Unique R&D Engine



Our first products...

Platech

N4CELLS

Human growth factors for cell culture

MegaProt

Human recombinant proteins
(the hard ones)

- **We solve the pains**: consistency, safety, cost, and precision.
- Our proteins deliver human-grade performance with **up to 15× lower cost** and **10× higher efficiency** than current alternatives.
- Also, Platech operates a **CRO platform** for on-demand production of complex human proteins.

Global Validations: Sartorius CellGenix (Now part of Sartorius), Merck (In progress)

Commercial traction: (early adopters) Universidad Técnica Federico Santa María, MEDICEL, Universidad Andrés Bello, Universidad de Valparaíso Chile, Atacama Bio Natural Products S.A.

In this context, the proteins manufactured at Platech address these challenges across diverse global applications



Applications Levels

- Manufacturing process
- Clinical Trials — Next steps
- R&D Preclinical trials
- R&D hCell culture assays

Target Market – Impact in Multiple Markets

Expand

Our Market Reach



TAM
Human proteins for cell culture, biomanufacturing, primary cells, and stem cells.

SAM
Consider the market for human proteins for use in experimentation and treatment of human cells.

SOM
Consider specifically human growth factors, in mix or recombinant type, for use in cell culture,

Platech
Platelet Technologies

Business Model Strategy

TO REDUCE RISKS AND APPROACH THE INDUSTRY

We aim to generate purchase orders and validate the technology to license our products. Beyond licensing, there's industry interest in our growth factors and in operating as DhP suppliers — supported by our plan to establish a parallel manufacturing line and on-demand CDMO-like services.

Merck – Cytiva – ThermoFisher – Sartorius - Others

Platech
Platelet Technologies

TIMELINE

History and Trajectory

TIMELINE

History and Trajectory

2015

- On December the 29th we founded Platelets Technologies in Santiago of Chile.
- Pre seed USD20.000
- Grant CORFO 35.000

2017

- Platform development at laboratory scale.
- First draft of the IP strategy
- Seed USD250.000
- Grant CORFO USD200.000

2018

- Platech facilities are finished.
- Identification of value elements for trade secret protection and patenting.
- Business model validation.

2019

- Platform Bioprocess scaled to 1L.
- Registration of the Platech trademark
- Pre serie A USD1.300.000



TIMELINE

History and Trajectory

2020

- First version of Human Growth Factors.
- Pipelines, documentation, and traceability
- Grant CORFO USD300.000

2021-22

- Continuous development of the HGFs.
- Initial valuation model
- New value elements in the IP strategy

2023

- Platform reaches Industrial Scale.
- New products.
- Grant CORFO USD200.000
- Bridge capital

2024-25

- First recombinant proteins are produced.
- Global validation
- Execution of the technology-transfer model via licensing
- New areas, new IP models, and new business models




THANK
YOU
Platech
Platelet Technologies

Groundbreaking innovations are taking shape at Platech

Join us now and help drive the next scientific leap!

Platech
Platelet Technologies

Patricio Avila Peña – CEO
patavilap@platech.cl – +56967260554